{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:37:22Z","timestamp":1790397442206,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["5U54GM104942-05"],"award-info":[{"award-number":["5U54GM104942-05"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40290-022-00446-8","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T20:23:27Z","timestamp":1666383807000},"page":"353-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-7445","authenticated-orcid":false,"given":"Yuni","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolbi L.","family":"Tonkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-4274","authenticated-orcid":false,"given":"Toni Marie","family":"Rudisill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"12","key":"446_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"GBD 2016 Alcohol and Drug Use Collaborators","year":"2018","unstructured":"GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatry"},{"key":"446_CR2","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health: Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021."},{"key":"446_CR3","unstructured":"National Conference of State Legislatures. State medical marijuana laws. 2021. https:\/\/www.ncsl.org\/research\/health\/state-medical-marijuana-laws.aspx. Accessed 10 Oct 2021."},{"key":"446_CR4","unstructured":"US Food and Drug Administration. FDA and cannabis: research and drug approval process. 2020. https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-and-cannabis-research-and-drug-approval-process. Accessed 16 Aug 2022."},{"key":"446_CR5","unstructured":"Department of Justice. Cannabis legalization and regulation. 2021. Available from: https:\/\/www.justice.gc.ca\/eng\/cj-jp\/cannabis\/. Accessed 20 Feb 2020."},{"key":"446_CR6","unstructured":"Australian Government. Narcotic Drugs Amendment Act, No.12, 2016. Federal Register of Legislation; 2016."},{"key":"446_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100080","volume":"7","author":"B Fischer","year":"2021","unstructured":"Fischer B, Hall W. New Zealand\u2019s failed cannabis legalization referendum: implications for cannabis policy reform. Lancet Reg Health West Pac. 2021;7: 100080.","journal-title":"Lancet Reg Health West Pac."},{"key":"446_CR8","unstructured":"Kilburn & Strode LLP. Cannabis: a brief overview of US and European approaches. 2021. https:\/\/www.kilburnstrode.com\/knowledge\/european-ip\/cannabis-us-and-european-approaches. Accessed 20 Feb 2022."},{"key":"446_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1141","volume":"365","author":"TP Freeman","year":"2019","unstructured":"Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ. 2019;365: l1141.","journal-title":"BMJ"},{"key":"446_CR10","volume-title":"Marijuana and medicine: assessing the science vase","author":"Institute of Medicine","year":"1999","unstructured":"Institute of Medicine. Marijuana and medicine: assessing the science vase. Washington, DC: The National Academies Press; 1999."},{"issue":"5","key":"446_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrn.2016.28","volume":"17","author":"HV Curran","year":"2016","unstructured":"Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17(5):293\u2013306.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"446_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27(1):19\u201327.","journal-title":"J Psychopharmacol"},{"key":"446_CR13","unstructured":"National Institute on Drug Abuse. Is marijuana safe and effective as medicine? 13 April 2021. https:\/\/nida.nih.gov\/publications\/research-reports\/marijuana\/marijuana-safe-effective-medicine. Access date was May 1, 2022"},{"issue":"2","key":"446_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","volume":"39","author":"JR Johnson","year":"2010","unstructured":"Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167\u201379.","journal-title":"J Pain Symptom Manage"},{"key":"446_CR15","unstructured":"US Food and Drug Administration. FDA approves new indication for drug containing an active ingredient derived from cannabis to treat seizures in rare genetic disease. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare#:~:text=Today%2C%20the%20U.S.%20Food%20and,year%20of%20age%20and%20older. Accessed 30 Aug 2022."},{"key":"446_CR16","unstructured":"US Drug Enforcement Administration. Drug scheduling. 2018. https:\/\/www.dea.gov\/drug-information\/drug-scheduling. Accessed 16 Aug 2022."},{"key":"446_CR17","unstructured":"US Department of Agriculture. Hemp. 2022. https:\/\/www.usda.gov\/topics\/hemp#:~:text=The%20Agriculture%20Improvement%20Act%20of%202018%20(2018%20Farm%20Bill)%20authorized,DEA)%20schedule%20of%20Controlled%20Substances. Accessed 22 Feb 2022."},{"issue":"1","key":"446_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000489287","volume":"1","author":"A Hazekamp","year":"2018","unstructured":"Hazekamp A. The trouble with CBD oil. Med Cannabis Cannabinoids. 2018;1(1):65\u201372.","journal-title":"Med Cannabis Cannabinoids."},{"key":"446_CR19","unstructured":"Mikulic M. Total U.S. cannabidiol (CBD) product sales 2014-2022. 2021. https:\/\/www.statista.com\/statistics\/760498\/total-us-cbd-sales\/. Accessed 22 Feb 2022."},{"issue":"3","key":"446_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","volume":"35","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, et al. Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet syndrome and Lennox-Gastaut syndrome. CNS Drugs. 2021;35(3):265\u201381.","journal-title":"CNS Drugs"},{"issue":"3","key":"446_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Striano P, Del Giovane C, et al. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34(3):229\u201341.","journal-title":"CNS Drugs"},{"issue":"17","key":"446_CR22","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78(17):1791\u2013804.","journal-title":"Drugs"},{"issue":"10","key":"446_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","volume":"32","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M. Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis. CNS Drugs. 2018;32(10):905\u201316.","journal-title":"CNS Drugs"},{"issue":"7","key":"446_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2017-317168","volume":"89","author":"E Stockings","year":"2018","unstructured":"Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"446_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/can.2018.0006","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res. 2018;3(1):152\u201361.","journal-title":"Cannabis Cannabinoid Res."},{"issue":"9","key":"446_CR26","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/bcp.14038","volume":"85","author":"SA Millar","year":"2019","unstructured":"Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O\u2019Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 2019;85(9):1888\u2013900.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"446_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.14740\/jocmr4090","volume":"12","author":"C Larsen","year":"2020","unstructured":"Larsen C, Shahinas J. Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res. 2020;12(3):129\u201341.","journal-title":"J Clin Med Res"},{"issue":"11","key":"446_CR28","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020;45(11):1799\u2013806.","journal-title":"Neuropsychopharmacology"},{"key":"446_CR29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","volume":"107","author":"AM Freeman","year":"2019","unstructured":"Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review Neurosci Biobehav Rev. 2019;107:696\u2013712.","journal-title":"A systematic review. Neurosci Biobehav Rev."},{"issue":"6","key":"446_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/medicina56060309","volume":"56","author":"L Poyatos","year":"2020","unstructured":"Poyatos L, P\u00e9rez-Acevedo AP, Papaseit E, P\u00e9rez-Ma\u00f1\u00e1 C, Martin S, Hladun O, et al. Oral administration of cannabis and \u0394-9-tetrahydrocannabinol (THC) preparations: a systematic review. Medicina (Kaunas). 2020;56(6):309.","journal-title":"Medicina (Kaunas)"},{"key":"446_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101339","volume":"53","author":"AS Suraev","year":"2020","unstructured":"Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, et al. Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Sleep Med Rev. 2020;53: 101339.","journal-title":"Sleep Med Rev"},{"issue":"12","key":"446_CR32","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995\u20131010.","journal-title":"Lancet Psychiatry"},{"issue":"101","key":"446_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.109900","volume":"13","author":"MO Ogunbiyi","year":"2020","unstructured":"Ogunbiyi MO, Hindocha C, Freeman TP, Bloomfield MAP. Acute and chronic effects of \u0394(9)-tetrahydrocannabinol (THC) on cerebral blood flow: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2020;13(101): 109900.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"446_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/jcbfm.2014.218","volume":"35","author":"TJ England","year":"2015","unstructured":"England TJ, Hind WH, Rasid NA, O\u2019Sullivan SE. Cannabinoids in experimental stroke: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2015;35(3):348\u201358.","journal-title":"J Cereb Blood Flow Metab"},{"key":"446_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.neubiorev.2016.03.010","volume":"64","author":"M Colizzi","year":"2016","unstructured":"Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S. Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci Biobehav Rev. 2016;64:359\u201381.","journal-title":"Neurosci Biobehav Rev"},{"issue":"Suppl. 1","key":"446_CR36","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/j.pain.0000000000002269","volume":"162","author":"N Soliman","year":"2021","unstructured":"Soliman N, Haroutounian S, Hohmann AG, Krane E, Liao J, Macleod M, et al. Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain. 2021;162(Suppl. 1):S26-44.","journal-title":"Pain"},{"key":"446_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106635","volume":"102","author":"RR de Carvalho","year":"2020","unstructured":"de Carvalho RR, Almeida KJ, da Silva LL, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis. Epilepsy Behav. 2020;102: 106635.","journal-title":"Epilepsy Behav"},{"key":"446_CR38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","volume":"74","author":"S Bonaccorso","year":"2019","unstructured":"Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology. 2019;74:282\u201398.","journal-title":"Neurotoxicology"},{"issue":"1","key":"446_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42238-019-0012-y","volume":"2","author":"R Khan","year":"2020","unstructured":"Khan R, Naveed S, Mian N, Fida A, Raafey MA, Aedma KK. The therapeutic role of cannabidiol in mental health: a systematic review. J Cannabis Res. 2020;2(1):2.","journal-title":"J Cannabis Res."},{"key":"446_CR40","unstructured":"Silva EAD, Medeiros WMB, Torro N, Sousa JMM, Almeida IBCM, Costa FBD, Pontes KM, Nunes ELG, Rosa MDD, Albuquerque KLGD. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends Psychiatry Psychother. 2022 Jun 13;44:e20200149."},{"issue":"1","key":"446_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.japh.2019.11.008","volume":"60","author":"JW Skelley","year":"2020","unstructured":"Skelley JW, Deas CM, Curren Z, Ennis J. Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003). 2020;60(1):253\u201361.","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"446_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"446_CR43","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019.","DOI":"10.1002\/9781119536604"},{"issue":"4","key":"446_CR44","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","volume":"237","author":"E Appiah-Kusi","year":"2020","unstructured":"Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology. 2020;237(4):1121\u201330.","journal-title":"Psychopharmacology"},{"issue":"11","key":"446_CR45","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S, Wilson R, Appiah-Kusi E, O\u2019Neill A, Brammer M, Perez J, et al. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiat. 2018;75(11):1107\u201317.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"446_CR46","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/ibd\/izz017","volume":"25","author":"DG Couch","year":"2019","unstructured":"Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O\u2019Sullivan SE. Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo: a randomized, placebo-controlled, double-blind controlled trial. Inflamm Bowel Dis. 2019;25(6):1006\u201318.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"446_CR47","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","volume":"226","author":"RK Das","year":"2013","unstructured":"Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology. 2013;226(4):781\u201392.","journal-title":"Psychopharmacology"},{"issue":"1","key":"446_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41398-020-0862-2","volume":"10","author":"C Davies","year":"2020","unstructured":"Davies C, Wilson R, Appiah-Kusi E, Blest-Hopley G, Brammer M, Perez J, et al. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry. 2020;10(1):311.","journal-title":"Transl Psychiatry"},{"issue":"6","key":"446_CR49","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","volume":"17","author":"RM Freeman","year":"2006","unstructured":"Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):636\u201341.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"10","key":"446_CR50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020;7(10):865\u201374.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"446_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","volume":"66","author":"P Fusar-Poli","year":"2009","unstructured":"Fusar-Poli P, Crippa J, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of A9-Tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66(1):95\u2013105.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"446_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12762","volume":"25","author":"C Hindocha","year":"2020","unstructured":"Hindocha C, Freeman TP, Schafer G, Gardner C, Bloomfield MAP, Bramon E, et al. Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme. Addict Biol. 2020;25(3): e12762.","journal-title":"Addict Biol"},{"issue":"3","key":"446_CR53","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0269881117737400","volume":"32","author":"H Hundal","year":"2018","unstructured":"Hundal H, Lister R, Evans N, Antley A, Englund A, Murray RM, et al. The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol. 2018;32(3):276\u201382.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"446_CR54","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/ibd\/izy002","volume":"24","author":"PM Irving","year":"2018","unstructured":"Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24(4):714\u201324.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"446_CR55","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2337\/dc16-0650","volume":"39","author":"KA Jadoon","year":"2016","unstructured":"Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39(10):1777\u201386.","journal-title":"Diabetes Care"},{"issue":"3","key":"446_CR56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175(3):225\u201331.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"446_CR57","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"CJA Morgan","year":"2013","unstructured":"Morgan CJA, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38(9):2433\u20136.","journal-title":"Addict Behav"},{"issue":"1","key":"446_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41398-018-0191-x","volume":"8","author":"CJA Morgan","year":"2018","unstructured":"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry. 2018;8(1):181.","journal-title":"Transl Psychiatry"},{"issue":"5","key":"446_CR59","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2044.2004.03674.x","volume":"59","author":"W Notcutt","year":"2004","unstructured":"Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 \u201cN of 1\u201d studies. Anaesthesia. 2004;59(5):440\u201352.","journal-title":"Anaesthesia"},{"issue":"4","key":"446_CR60","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/S0033291719003519","volume":"51","author":"A O'Neill","year":"2021","unstructured":"O\u2019Neill A, Wilson R, Blest-Hopley G, Annibale L, Colizzi M, Brammer M, et al. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med. 2021;51(4):596\u2013606.","journal-title":"Psychol Med"},{"issue":"9","key":"446_CR61","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/0269881119858306","volume":"33","author":"CM Pretzsch","year":"2019","unstructured":"Pretzsch CM, Voinescu B, Mendez MA, Wichers R, Ajram L, Ivin G, et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol. 2019;33(9):1141\u20138.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"446_CR62","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","volume":"44","author":"CM Pretzsch","year":"2019","unstructured":"Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019;44(8):1398\u2013405.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"446_CR63","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/bcp.14225","volume":"86","author":"SR Sultan","year":"2020","unstructured":"Sultan SR, O\u2019Sullivan SE, England TJ. The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: a randomised controlled trial. Br J Clin Pharmacol. 2020;86(6):1125\u201338.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"446_CR64","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/01.ijg.0000212260.04488.60","volume":"15","author":"I Tomida","year":"2006","unstructured":"Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349\u201353.","journal-title":"J Glaucoma"},{"issue":"1","key":"446_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1191\/0269215503cr581oa","volume":"17","author":"DT Wade","year":"2003","unstructured":"Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17(1):21\u20139.","journal-title":"Clin Rehabil"},{"key":"446_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-019-0534-2","volume":"9","author":"R Wilson","year":"2019","unstructured":"Wilson R, Bossong MG, Appiah-Kusi E, Petros N, Brammer M, Perez J, et al. Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. Transl Psychiatry. 2019;9:1\u201310.","journal-title":"Transl Psychiatry"},{"key":"446_CR67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","volume":"172","author":"S Babalonis","year":"2017","unstructured":"Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017;172:9\u201313.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"446_CR68","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"35","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology. 2018;35(7):1923\u201332.","journal-title":"Psychopharmacology"},{"issue":"3","key":"446_CR69","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al. Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav. 1991;40(3):701\u20138.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"446_CR70","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0091-3057(91)90357-8","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Kennedy K, Schram K. Assay of plasma cannabidiol by capillary gas chromatography\/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav. 1991;40(3):517\u201322.","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"446_CR71","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/npp.2015.367","volume":"41","author":"M Haney","year":"2016","unstructured":"Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology. 2016;41(8):1974\u201382.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"446_CR72","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","volume":"176","author":"YL Hurd","year":"2019","unstructured":"Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176(11):911\u201322.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"446_CR73","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/da.23032","volume":"37","author":"RR Kayser","year":"2020","unstructured":"Kayser RR, Haney M, Raskin M, Arout C, Simpson HB. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: a human laboratory study. Depress Anxiety. 2020;37(8):801\u201311.","journal-title":"Depress Anxiety"},{"issue":"3","key":"446_CR74","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","volume":"9","author":"AF Manini","year":"2015","unstructured":"Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015;9(3):204\u201310.","journal-title":"J Addict Med"},{"issue":"3","key":"446_CR75","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00004714-198105000-00004","volume":"1","author":"SS Matsuyama","year":"1981","unstructured":"Matsuyama SS, Fu TK. In vivo cytogenetic effects of cannabinoids. J Clin Psychopharmacol. 1981;1(3):135\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"446_CR76","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.neuropharm.2018.03.036","volume":"135","author":"PD Skosnik","year":"2018","unstructured":"Skosnik PD, Haj\u00f3s M, Cortes-Briones JA, Edwards CR, Pittman BP, Hoffmann WE, et al. Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: a translational study in rats and humans. Neuropharmacology. 2018;135:412\u201323.","journal-title":"Neuropharmacology"},{"issue":"2","key":"446_CR77","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jat\/bkz080","volume":"44","author":"TR Spindle","year":"2019","unstructured":"Spindle TR, Cone EJ, Kuntz D, Mitchell JM, Bigelow GE, Flegel R, et al. Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis. J Anal Toxicol. 2019;44(2):109\u201325.","journal-title":"J Anal Toxicol"},{"issue":"5","key":"446_CR78","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/1389201020666191202111534","volume":"21","author":"DH Xu","year":"2020","unstructured":"Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020;21(5):390\u2013402.","journal-title":"Curr Pharm Biotechnol"},{"issue":"6","key":"446_CR79","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RHC, Chagas MHN, De Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-nave social phobia patients. Neuropsychopharmacology. 2011;36(6):1219\u201326.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"446_CR80","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28(11):1088\u201392.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"446_CR81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF00431988","volume":"66","author":"P Consroe","year":"1979","unstructured":"Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. Psychopharmacology. 1979;66(1):45\u201350.","journal-title":"Psychopharmacology"},{"issue":"2","key":"446_CR82","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0269881119895536","volume":"34","author":"SM de Faria","year":"2020","unstructured":"de Faria SM, de Morais FD, Tumas V, Castro PC, Ponti MA, Hallak JE, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson\u2019s disease. J Psychopharmacol. 2020;34(2):189\u201396.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"446_CR83","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pnpbp.2010.11.002","volume":"35","author":"JEC Hallak","year":"2011","unstructured":"Hallak JEC, Dursun SM, Bosi DC, de Macedo LRH, Machado-de-Sousa JP, Abrao J, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(1):198\u2013202.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"446_CR84","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2018.00315","volume":"9","author":"IMP Linares","year":"2018","unstructured":"Linares IMP, Guimaraes FS, Eckeli A, Crippa ACS, Zuardi AW, Souza JD, et al. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol. 2018;9:315.","journal-title":"Front Pharmacol"},{"issue":"1","key":"446_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","volume":"41","author":"IM Linares","year":"2019","unstructured":"Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimar\u00e3es FS, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019;41(1):9\u201314.","journal-title":"Braz J Psychiatry."},{"issue":"5","key":"446_CR86","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","volume":"43","author":"C Meneses-Gaya","year":"2021","unstructured":"Meneses-Gaya C, Crippa JA, Hallak JE, Miguel AQ, Laranjeira R, Bressan RA, et al. Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Braz J Psychiatry. 2021;43(5):467\u201376.","journal-title":"Braz J Psychiatry."},{"issue":"3","key":"446_CR87","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","volume":"76","author":"AW Zuardi","year":"1982","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by \u03b49-THC in normal subjects. Psychopharmacology. 1982;76(3):245\u201350.","journal-title":"Psychopharmacology"},{"issue":"1","key":"446_CR88","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","volume":"7","author":"AW Zuardi","year":"1993","unstructured":"Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol. 1993;7(1):82\u20138.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"446_CR89","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300340","volume":"29","author":"JA De Souza Crippa","year":"2004","unstructured":"De Souza Crippa JA, Zuardi AW, Garrido GEJ, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417\u201326.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"446_CR90","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00496070","volume":"64","author":"BE Belgrave","year":"1979","unstructured":"Belgrave BE, Bird KD, Chesher GB, Jackson DM, Lubble KE, Starmer GA, et al. The effect of cannabidiol, alone and in combination with ethanol, on human performance. Psychopharmacology. 1979;64(2):243\u20136.","journal-title":"Psychopharmacology"},{"issue":"2","key":"446_CR91","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/bcp.14399","volume":"87","author":"D Efron","year":"2021","unstructured":"Efron D, Freeman JL, Cranswick N, Payne JM, Mulraney M, Prakash C, et al. A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability. Br J Clin Pharmacol. 2021;87(2):436\u201346.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"446_CR92","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1111\/bcp.14617","volume":"87","author":"A Hosseini","year":"2021","unstructured":"Hosseini A, McLachlan AJ, Lickliter JD. A phase I trial of the safety, tolerability, and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Br J Clin Pharmacol. 2021;87(4):2020\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"446_CR93","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s13318-020-00624-6","volume":"45","author":"D Perkins","year":"2020","unstructured":"Perkins D, Butler J, Ong K, Nguyen TH, Cox S, Francis B, et al. A phase 1, randomised, placebo-controlled, dose escalation study to investigate the safety, tolerability and pharmacokinetics of cannabidiol in fed healthy volunteers. Eur J Drug Metab Pharmacokinet. 2020;45(5):575\u201386.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"446_CR94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","volume":"269","author":"N Solowij","year":"2019","unstructured":"Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, et al. A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):17\u201335.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"21","key":"446_CR95","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1001\/jama.2020.21218","volume":"324","author":"TR Arkell","year":"2020","unstructured":"Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of cannabidiol and \u03949-tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA. 2020;324(21):2177\u201386.","journal-title":"JAMA"},{"issue":"1","key":"446_CR96","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1089\/can.2017.0018","volume":"2","author":"SEM De Bruijn","year":"2017","unstructured":"De Bruijn SEM, De Graaf C, Witkamp RF, Jager G. Explorative placebo-controlled double-blind intervention study with low doses of inhaled DELTA9-tetrahydrocannabinol and cannabidiol reveals no effect on sweet taste intensity perception and liking in humans. Cannabis Cannabinoid Res. 2017;2(1):114\u201322.","journal-title":"Cannabis Cannabinoid Res."},{"issue":"11","key":"446_CR97","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053\u201367.","journal-title":"CNS Drugs"},{"key":"446_CR98","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:7.","journal-title":"Transl Psychiatry"},{"issue":"6","key":"446_CR99","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10620-017-4540-z","volume":"62","author":"T Naftali","year":"2017","unstructured":"Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn\u2019s disease, a randomized controlled trial. Dig Dis Sci. 2017;62(6):1615\u201320.","journal-title":"Dig Dis Sci"},{"key":"446_CR100","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","volume":"88","author":"KA Schoedel","year":"2018","unstructured":"Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav. 2018;88:162\u201371.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"446_CR101","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-0030-1267062","volume":"1","author":"J Dettori","year":"2010","unstructured":"Dettori J. The random allocation process: two things you need to know. Evid Based Spine Care J. 2010;1(3):7\u20139.","journal-title":"Evid Based Spine Care J."},{"issue":"1","key":"446_CR102","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","volume":"3","author":"J Moltke","year":"2021","unstructured":"Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res. 2021;3(1):5.","journal-title":"J Cannabis Res."},{"issue":"8","key":"446_CR103","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","volume":"34","author":"E Perucca","year":"2020","unstructured":"Perucca E, Bialer M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs. 2020;34(8):795\u2013800.","journal-title":"CNS Drugs"},{"issue":"10","key":"446_CR104","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","volume":"17","author":"MA Huestis","year":"2019","unstructured":"Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busard\u00f2 FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019;17(10):974\u201389.","journal-title":"Curr Neuropharmacol"},{"key":"446_CR105","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15844\/pedneurbriefs-32-3","volume":"32","author":"DA Freedman","year":"2018","unstructured":"Freedman DA, Patel AD. Inadequate regulation contributes to mislabeled online cannabidiol products. Pediatr Neurol Briefs. 2018;32:3.","journal-title":"Pediatr Neurol Briefs."},{"issue":"5","key":"446_CR106","first-page":"394","volume":"117","author":"DG Evans","year":"2020","unstructured":"Evans DG. Medical fraud, mislabeling, contamination: all common in CBD products. Mo Med. 2020;117(5):394\u20139.","journal-title":"Mo Med"},{"issue":"17","key":"446_CR107","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2017.11909","volume":"318","author":"MO Bonn-Miller","year":"2017","unstructured":"Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708\u20139.","journal-title":"JAMA"},{"issue":"2","key":"446_CR108","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1741-6787.2006.00051.x","volume":"3","author":"KM Benzies","year":"2006","unstructured":"Benzies KM, Premji S, Hayden KA, Serrett K. State-of-the-evidence reviews: advantages and challenges of including grey literature. Worldviews Evid Based Nurs. 2006;3(2):55\u201361.","journal-title":"Worldviews Evid Based Nurs."},{"issue":"9237","key":"446_CR109","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(00)02786-0","volume":"356","author":"L McAuley","year":"2000","unstructured":"McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356(9237):1228\u201331.","journal-title":"Lancet"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-022-00446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-022-00446-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-022-00446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T10:50:53Z","timestamp":1701255053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-022-00446-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40290-022-00446-8","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"30 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TMR received financial support from the National Institute of General Medical Sciences of the National Institutes of Health under Award Number 5U54GM104942-05. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"We have made all data that were extracted for this article available in the Electronic Supplementary Material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"YT, KT, and TMR conceived and designed the study. YT and KT conducted the literature search, selection process, and data extraction. YT and KT analyzed the data. TMR supervised the search, selection, data extraction, and analysis. YT wrote the first draft of the manuscript and all authors commented and edited previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}